Proteasome inhibition reduces plasma cell and antibody secretion, but not angiotensin II-induced hypertension.
angiotensin II
antibody secreting cells
bortezomib
hypertension
immunoglobulins
plasma cells
proteasome inhibition
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
03
2023
accepted:
17
05
2023
medline:
19
6
2023
pubmed:
19
6
2023
entrez:
19
6
2023
Statut:
epublish
Résumé
Depletion of mature B cells affords protection against experimental hypertension. However, whether B cell-mediated hypertension is dependent on differentiation into antibody-secreting cells (ASCs) remains unclear. Using the proteasome inhibitor, bortezomib, the present study tested the effect of ASC reduction on angiotensin II-induced hypertension. Male C57BL6/J mice were infused with angiotensin II (0.7 mg/kg/day; s.c.) for 28 days via osmotic minipump to induce hypertension. Normotensive control mice received saline infusion. Bortezomib (750 μg/kg) or vehicle (0.1% DMSO) was administered (i.v.) 3 days prior to minipump implantation, and twice weekly thereafter. Systolic blood pressure was measured weekly using tail-cuff plethysmography. Spleen and bone marrow B1 (CD19 Bortezomib treatment reduced splenic ASCs by ∼68% and ∼64% compared to vehicle treatment in normotensive (2.00 ± 0.30 vs. 0.64 ± 0.15 × 10 Reductions in ASCs and circulating IgG2a and IgM did not ameliorate experimental hypertension, suggesting other immunoglobulin isotypes or B cell effector functions may promote angiotensin II-induced hypertension.
Identifiants
pubmed: 37332591
doi: 10.3389/fcvm.2023.1184982
pmc: PMC10272792
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1184982Informations de copyright
© 2023 Figueiredo Galvao, Dinh, Thomas, Wassef, Diep, Bobik, Sobey, Drummond and Vinh.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Structure. 2006 Mar;14(3):451-6
pubmed: 16531229
Cardiovasc Res. 2018 Mar 01;114(3):456-467
pubmed: 29324984
J Immunol. 2011 Feb 15;186(4):2503-13
pubmed: 21239719
Sci Transl Med. 2015 Oct 21;7(310):310ra166
pubmed: 26491076
Immunol Lett. 1984;8(3):143-5
pubmed: 6500633
J Exp Med. 2006 Oct 30;203(11):2541-50
pubmed: 17060475
Br Med J. 1970 Apr 18;2(5702):146-8
pubmed: 4985868
Cardiovasc Res. 2021 Mar 21;117(4):1217-1228
pubmed: 32609312
Rheumatol Ther. 2020 Sep;7(3):433-446
pubmed: 32488652
Nat Rev Immunol. 2011 Jan;11(1):34-46
pubmed: 21151033
Cell Death Differ. 2008 Mar;15(3):600-12
pubmed: 18188168
Hypertension. 2018 Apr;71(4):719-728
pubmed: 29378858
Leukemia. 2007 Apr;21(4):838-42
pubmed: 17268529
Cardiol Rev. 2018 May/Jun;26(3):122-129
pubmed: 29077585
Nat Commun. 2019 Oct 18;10(1):4768
pubmed: 31628339
Immunity. 2007 Feb;26(2):191-203
pubmed: 17292640
Nat Commun. 2017 Sep 21;8(1):641
pubmed: 28935935
Nat Rev Immunol. 2013 Feb;13(2):118-32
pubmed: 23348416
Lancet. 1981 Feb 21;1(8217):406-8
pubmed: 6110039
Nat Med. 2008 Jul;14(7):748-55
pubmed: 18542049
Methods Mol Biol. 2017;1535:339-351
pubmed: 27914091
Immunity. 2014 Dec 18;41(6):1040-51
pubmed: 25484301
J Hypertens. 1989 Feb;7(2):91-5
pubmed: 2647845
Eur J Immunol. 2017 Aug;47(8):1276-1279
pubmed: 28787106
Eur J Immunol. 2017 Aug;47(8):1386-1388
pubmed: 28654161
Hypertension. 2019 Mar;73(3):561-570
pubmed: 30636551
Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6293-8
pubmed: 16606838
Exp Hematol Oncol. 2012 Nov 29;1(1):36
pubmed: 23210908
J Mol Cell Cardiol. 2015 Feb;79:303-14
pubmed: 25526681
Circulation. 2010 Dec 14;122(24):2529-37
pubmed: 21126972
Nat Rev Immunol. 2019 Aug;19(8):517-532
pubmed: 30992524
Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):296-302
pubmed: 25359862
Nat Commun. 2020 Aug 10;11(1):3989
pubmed: 32778653
Front Immunol. 2016 Sep 09;7:324
pubmed: 27667991
Cardiovasc Res. 2022 Nov 10;118(14):2985-2999
pubmed: 35048969
Arthritis Rheum. 2006 Jan;54(1):192-201
pubmed: 16385515
Eur J Immunol. 2015 Apr;45(4):988-98
pubmed: 25645456
J Exp Med. 2007 Oct 1;204(10):2449-60
pubmed: 17875676
Arterioscler Thromb Vasc Biol. 2018 May;38(5):e71-e84
pubmed: 29599140
Sci Adv. 2018 Jul 11;4(7):eaas9944
pubmed: 30009261
Life Sci. 1998;63(4):PL65-70
pubmed: 9698041
Hypertension. 2015 Nov;66(5):1023-33
pubmed: 26351030
Hypertension. 2014 Oct;64(4):792-800
pubmed: 25024282
J Exp Med. 2012 May 7;209(5):1001-10
pubmed: 22547654
Ann Rheum Dis. 2011 Nov;70(11):2022-8
pubmed: 21742639
J Exp Med. 1999 May 17;189(10):1639-48
pubmed: 10330443
PLoS One. 2013 Oct 30;8(10):e78564
pubmed: 24205262
J Immunol. 2012 Aug 1;189(3):1322-9
pubmed: 22732592
Clin J Am Soc Nephrol. 2016 Jan 7;11(1):137-54
pubmed: 26700440
Cardiovasc Res. 2016 Sep;111(4):385-97
pubmed: 27492217
Eur J Immunol. 2012 Jan;42(1):120-9
pubmed: 22009734
J Mol Med (Berl). 2009 Aug;87(8):793-802
pubmed: 19399470